Quince Therapeutics, Inc.
For the period ended Sep 30, 2025. Filed Nov 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 12, 2025
QNCX$31.73+8.1%Stored close · as of Oct 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| Operating expenses: | ||||
| Research and development | $8,083 | $4,916 | $22,781 | $12,765 |
| General and administrative | 3,281 | 3,630 | 11,412 | 13,296 |
| Goodwill impairment charge | — | — | — | 17,130 |
| Fair value adjustment for contingent consideration | 2,066 | (2,683) | 4,522 | 2,082 |
| Total operating expenses | 13,430 | 5,863 | 38,715 | 45,273 |
| Loss from operations | (13,430) | (5,863) | (38,715) | (45,273) |
| Fair value adjustment for debt | (549) | (449) | (1,494) | (1,252) |
| Fair value adjustment for warrants | 291 | — | (4,173) | — |
| Warrant issuance costs | (42) | — | (914) | — |
| Interest income | 300 | 683 | 1,017 | 2,393 |
| Other income (expense), net | (58) | 150 | (174) | (158) |
| Net loss before income tax expense | (13,488) | (5,479) | (44,453) | (44,290) |
| Income tax benefit (expense) | 46 | (13) | (68) | (80) |
| Net loss | (13,442) | (5,492) | (44,521) | (44,370) |
| Other comprehensive loss: | ||||
| Foreign currency translation adjustments | 125 | 2,158 | 6,386 | 203 |
| Unrealized gain (loss) on available-for-sale securities | 12 | 174 | (58) | 169 |
| Total comprehensive loss | $(13,305) | $(3,160) | $(38,193) | $(43,998) |
| Net loss per share - basic and diluted | $(0.25) | $(0.13) | $(0.92) | $(1.03) |
| Weighted average shares of common stock outstanding - basic and diluted | 53,951,371 | 43,164,136 | 48,234,306 | 43,090,632 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.